查看購物車
  • English
封面
市場調查報告書
商品編碼
1914550

藥物警戒市場－全球產業規模、佔有率、趨勢、機會及預測（按臨床試驗階段、方法、服務供應商、流程、治療領域、最終用戶、地區和競爭格局分類，2021-2031年）

Pharmacovigilance Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Clinical Trial Phase, By Method, By Service Provider, By Process Flow, By Therapeutic Area, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球藥物監測市場預計將從2025年的82.1億美元顯著成長至2031年的153.7億美元，複合年成長率（CAGR）為11.02%。藥物監測是一個專注於檢測、評估、理解和預防不利事件及相關問題的科學領域，其主要驅動力是全球藥品消費量的成長以及需要長期用藥的慢性病患病率的上升。此外，世界各地衛生監管機構實施的嚴格監管要求迫使製藥公司建立嚴密的安全監測體系，這也成為推動該產業擴張的根本動力。

市場概覽
預測期 2027-2031
市場規模：2025年 82.1億美元
市場規模：2031年 153.7億美元
複合年成長率：2026-2031年 11.02%
成長最快的細分市場 合約外包
最大的市場 北美洲

儘管市場前景廣闊，但由於管理快速成長的安全資料量成本高且複雜，該市場仍面臨許多挑戰。數據量的爆炸性成長給現有資源帶來了巨大壓力，並需要建立強大的基礎設施。例如，歐洲藥品管理局 (EMA) 報告稱，2024 年向 EudraVigilance 提交的不利事件報告超過 170 萬份，這凸顯了各機構為確保合規性而必須準確收集和分析的資訊量之龐大。

市場促進因素

慢性病盛行率的上升以及由此導致的藥品消費量增加是全球藥物警戒市場的主要促進因素。隨著腫瘤、糖尿病和心血管疾病等疾病的全球負擔加重，用藥量也隨之增加，這需要對不利事件進行嚴格監測。世界衛生組織（世衛組織）於2024年2月發布的《2024年全球癌症現狀報告》也印證了這一趨勢，該報告預測2022年將新增2000萬例癌症病例，這意味著需要長期藥物治療的患者數量正在不斷成長。疾病發生率的上升迫使製藥公司擴大藥物警戒力度，以有效追蹤用於治療慢性病的複雜治療方法的安全性。

此外，臨床試驗和藥物研發的擴張正在推動市場成長，因為其產生大量安全數據，這些數據在核准前必須進行處理。製藥公司正大力投資創新技術以滿足尚未滿足的醫療需求，也增加了臨床試驗和上市後監管的需求。根據歐洲製藥工業協會聯合會（EFPIA）2024年6月發布的報告《2024年製藥業數據概覽》，預計2023年歐洲的研發支出將達到500億歐元。為了因應隨之而來的法律規範，各監管機構正在加強自身能力。 2024年，美國食品藥物管理局（FDA）申請了72億美元的2025會計年度預算，用於加強其安全項目和公共衛生基礎設施。

市場挑戰

安全數據的指數級成長對全球藥物警戒市場的擴張構成了重大障礙。隨著不利事件報告呈指數級成長，製藥公司被迫將大量資金用於維持基本的合規性，而非投資於創新。檢驗和處理如此龐大的資訊量既複雜又高成本，對企業造成了沉重的財務負擔，尤其是對中小企業而言。這些中小企業往往缺乏足夠的預算柔軟性來承擔嚴格的安全監測所需的高昂營運成本，這有效地限制了它們的市場參與度，並阻礙了整個產業的成長。

資源密集型環境因必須管理的龐大資訊量而進一步加劇，而這些資訊量之大正是避免監管處罰的必要條件。不斷加速的資料湧入迫使各組織優先考慮即時處理能力，而非長期策略發展。據烏普薩拉監測中心稱，2024年全球VigiBase系統平均每週收到約5萬份新的個案安全報告。如此龐大的數據湧入凸顯了相關人員被迫不斷擴展基礎設施才能滿足報告要求，最終阻礙了更廣泛的市場機會和盈利。

市場趨勢

人工智慧 (AI) 和機器學習的融合正在從根本上重塑全球藥物警戒市場，將安全營運從被動的合規轉向主動的風險管理。面對不利事件報告的激增，製藥公司正擴大利用預測演算法和自然語言處理技術來自動化諸如病例接收、療效檢查和敘述生成等勞動密集型任務。這項技術進步使安全團隊能夠專注於複雜的獲益-風險評估，而不是手動輸入數據​​，從而提高訊號檢測的速度和準確性。根據皮斯托亞聯盟 (Pistoia Alliance) 於 2025 年 9 月發布的《未來實驗室 2025 報告》，60% 的受訪者將人工智慧和機器學習列為未來兩年​​最重要的技術投資重點，凸顯了該行業對數位轉型的堅定承諾。

同時，由於需要在不承擔固定成本的情況下應對複雜的監管環境和不斷變化的資源需求，將部分工作策略性外包給合約研究組織 (CRO) 正逐漸成為主流趨勢。尤其是規模較小的公司，它們利用 CRO 的專業基礎設施來確保全球合規性和擴充性，從而有效地將固定營運成本轉化為可變支出。依賴外部合作夥伴使生物製藥公司能夠獲得先進的藥物警戒平台和全球安全網路，而這些平台和網路如果自行建造則成本極其高昂。根據臨床研究組織協會 (ACRO) 2025 年 7 月的報告顯示，其成員公司在 2024 年的收入預計將達到 980 億美元，這反映了目前外包給第三方供應商的工作規模之大。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球藥物警戒市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 臨床試驗階段（非臨床、1期、2期、3期、4期）
    • 依方法（自發性通報、增強型不良反應通報、有針對性的自發性通報、隊列心臟事件記錄器、電子健康記錄挖掘）
    • 按服務提供者（內部、合約外包）
    • 按流程（個案資料管理、訊號偵測、風險管理系統）
    • 依治療領域（腫瘤科、神經科、心臟科、其他）
    • 按最終用戶（製藥/生技公司、醫療設備製造商、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美藥物警戒市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲藥物警戒市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區藥物警戒市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲藥物警戒市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美藥物警戒市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球藥物警戒市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • IQVIA Inc.
  • ArisGlobal
  • Parexel International Corporation
  • Labcorp Drug Development
  • Accenture
  • Cognizant Technology Solutions
  • Ergomed Group
  • ICON plc
  • Syneos Health
  • Wipro Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 4809

The Global Pharmacovigilance Market is projected to experience substantial growth, rising from USD 8.21 Billion in 2025 to USD 15.37 Billion by 2031, reflecting a compound annual growth rate of 11.02%. Defined as the scientific discipline focused on detecting, assessing, understanding, and preventing adverse effects or medicine-related issues, the market is primarily driven by increasing global pharmaceutical consumption and the growing prevalence of chronic diseases that require long-term medication. Additionally, stringent regulatory requirements enforced by health authorities worldwide mandate that pharmaceutical companies maintain rigorous safety surveillance systems, serving as a fundamental driver for the industry's expansion.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.21 Billion
Market Size 2031USD 15.37 Billion
CAGR 2026-203111.02%
Fastest Growing SegmentContract Outsourcing
Largest MarketNorth America

Despite these growth prospects, the market faces a significant hurdle due to the high costs and complexity involved in managing the rapidly increasing volume of safety data. This surge in data places immense pressure on existing resources and necessitates the development of robust infrastructure. For instance, the European Medicines Agency reported that in 2024, over 1.7 million adverse drug reaction reports were submitted to EudraVigilance, underscoring the massive scale of information that organizations must accurately capture and analyze to ensure regulatory compliance.

Market Driver

The escalating prevalence of chronic diseases and the resulting increase in medication consumption serve as key catalysts for the Global Pharmacovigilance Market. As the global burden of conditions like oncology, diabetes, and cardiovascular disorders rises, the volume of administered drugs increases, necessitating strict monitoring for adverse events. Highlighting this trend, the World Health Organization's 'Global Status Report on Cancer 2024', released in February 2024, estimated there were 20 million new cancer cases in 2022, indicating a growing patient population that requires long-term pharmacological treatment. This rise in disease incidence compels pharmaceutical entities to expand their pharmacovigilance operations to effectively track the safety profiles of complex therapies used in chronic care.

Furthermore, the expansion of clinical trials and drug research and development accelerates market growth by generating vast amounts of safety data that must be processed before authorization. Pharmaceutical companies are investing heavily in innovation to meet unmet medical needs, heightening the demand for surveillance during both clinical and post-marketing phases. According to the European Federation of Pharmaceutical Industries and Associations' June 2024 report, 'The Pharmaceutical Industry in Figures 2024', R&D expenditure in Europe was projected to reach €50,000 million in 2023. To manage the regulatory oversight associated with this investment, agencies are also enhancing their capabilities; the US Food and Drug Administration requested a budget of $7.2 billion for fiscal year 2025 in 2024 to strengthen safety programs and public health infrastructure.

Market Challenge

The rapid increase in safety data volume poses a significant barrier to the Global Pharmacovigilance Market's expansion. As adverse event reports multiply exponentially, pharmaceutical companies are forced to divert substantial capital toward maintaining basic compliance rather than investing in innovation. The complexity and high expense of validating and processing this influx create a severe financial strain, particularly for small and medium-sized enterprises. These smaller entities often lack the budgetary flexibility to absorb the soaring operational costs required for rigorous safety surveillance, effectively limiting their participation in the market and hampering overall industry growth.

This resource-intensive environment is further exacerbated by the sheer scale of information that must be managed to avoid regulatory penalties. The relentless acceleration of data intake compels organizations to prioritize immediate processing capabilities over long-term strategic development. According to the Uppsala Monitoring Centre, the global VigiBase system received an average of approximately 50,000 new individual case safety reports per week in 2024. This magnitude of data influx highlights the immense pressure on industry stakeholders, who must continuously expand their infrastructure solely to keep pace with reporting requirements, thereby stifling broader market opportunities and profitability.

Market Trends

The integration of Artificial Intelligence and Machine Learning is fundamentally reshaping the Global Pharmacovigilance Market by shifting safety operations from reactive compliance to proactive risk management. Facing an exponential rise in adverse event reports, pharmaceutical companies are increasingly utilizing predictive algorithms and natural language processing to automate labor-intensive tasks such as case intake, validity checks, and narrative generation. This technological advancement allows safety teams to focus on complex benefit-risk assessments rather than manual data entry, improving the speed and accuracy of signal detection. According to the Pistoia Alliance's 'Lab of the Future 2025 Report' from September 2025, 60% of respondents identified AI and machine learning as their top technology investment for the next two years, underscoring the sector's commitment to digital transformation.

Simultaneously, strategic outsourcing to Contract Research Organizations (CROs) has emerged as a dominant trend, driven by the need to navigate complex regulatory landscapes and manage fluctuating resource demands without incurring fixed overheads. Small and medium-sized enterprises, in particular, are leveraging the specialized infrastructure of CROs to ensure global compliance and scalability, effectively converting fixed operational costs into variable expenses. This reliance on external partners enables bio-pharmaceutical firms to access advanced vigilance platforms and global safety networks that would be prohibitively expensive to build in-house. As reported by the Association of Clinical Research Organizations in July 2025, member companies generated an estimated $98 billion in revenue in 2024, reflecting the substantial scale of operations now entrusted to third-party providers.

Key Market Players

  • IQVIA Inc.
  • ArisGlobal
  • Parexel International Corporation
  • Labcorp Drug Development
  • Accenture
  • Cognizant Technology Solutions
  • Ergomed Group
  • ICON plc
  • Syneos Health
  • Wipro Limited

Report Scope

In this report, the Global Pharmacovigilance Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmacovigilance Market, By Clinical Trial Phase

  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

Pharmacovigilance Market, By Method

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Pharmacovigilance Market, By Service Provider

  • In-House
  • Contract Outsourcing

Pharmacovigilance Market, By Process Flow

  • Case Data Management
  • Signal Detection
  • Risk Management System

Pharmacovigilance Market, By Therapeutic Area

  • Oncology
  • Neurology
  • Cardiology
  • Others

Pharmacovigilance Market, By End-User

  • Pharmaceutical & Biotechnology Companies
  • Medical Device Manufacturers
  • Others

Pharmacovigilance Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmacovigilance Market.

Available Customizations:

Global Pharmacovigilance Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmacovigilance Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Clinical Trial Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3, Phase 4)
    • 5.2.2. By Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining)
    • 5.2.3. By Service Provider (In-House, Contract Outsourcing)
    • 5.2.4. By Process Flow (Case Data Management, Signal Detection, Risk Management System)
    • 5.2.5. By Therapeutic Area (Oncology, Neurology, Cardiology, Others)
    • 5.2.6. By End-User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Others)
    • 5.2.7. By Region
    • 5.2.8. By Company (2025)
  • 5.3. Market Map

6. North America Pharmacovigilance Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Clinical Trial Phase
    • 6.2.2. By Method
    • 6.2.3. By Service Provider
    • 6.2.4. By Process Flow
    • 6.2.5. By Therapeutic Area
    • 6.2.6. By End-User
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharmacovigilance Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Clinical Trial Phase
        • 6.3.1.2.2. By Method
        • 6.3.1.2.3. By Service Provider
        • 6.3.1.2.4. By Process Flow
        • 6.3.1.2.5. By Therapeutic Area
        • 6.3.1.2.6. By End-User
    • 6.3.2. Canada Pharmacovigilance Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Clinical Trial Phase
        • 6.3.2.2.2. By Method
        • 6.3.2.2.3. By Service Provider
        • 6.3.2.2.4. By Process Flow
        • 6.3.2.2.5. By Therapeutic Area
        • 6.3.2.2.6. By End-User
    • 6.3.3. Mexico Pharmacovigilance Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Clinical Trial Phase
        • 6.3.3.2.2. By Method
        • 6.3.3.2.3. By Service Provider
        • 6.3.3.2.4. By Process Flow
        • 6.3.3.2.5. By Therapeutic Area
        • 6.3.3.2.6. By End-User

7. Europe Pharmacovigilance Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Clinical Trial Phase
    • 7.2.2. By Method
    • 7.2.3. By Service Provider
    • 7.2.4. By Process Flow
    • 7.2.5. By Therapeutic Area
    • 7.2.6. By End-User
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharmacovigilance Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Clinical Trial Phase
        • 7.3.1.2.2. By Method
        • 7.3.1.2.3. By Service Provider
        • 7.3.1.2.4. By Process Flow
        • 7.3.1.2.5. By Therapeutic Area
        • 7.3.1.2.6. By End-User
    • 7.3.2. France Pharmacovigilance Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Clinical Trial Phase
        • 7.3.2.2.2. By Method
        • 7.3.2.2.3. By Service Provider
        • 7.3.2.2.4. By Process Flow
        • 7.3.2.2.5. By Therapeutic Area
        • 7.3.2.2.6. By End-User
    • 7.3.3. United Kingdom Pharmacovigilance Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Clinical Trial Phase
        • 7.3.3.2.2. By Method
        • 7.3.3.2.3. By Service Provider
        • 7.3.3.2.4. By Process Flow
        • 7.3.3.2.5. By Therapeutic Area
        • 7.3.3.2.6. By End-User
    • 7.3.4. Italy Pharmacovigilance Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Clinical Trial Phase
        • 7.3.4.2.2. By Method
        • 7.3.4.2.3. By Service Provider
        • 7.3.4.2.4. By Process Flow
        • 7.3.4.2.5. By Therapeutic Area
        • 7.3.4.2.6. By End-User
    • 7.3.5. Spain Pharmacovigilance Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Clinical Trial Phase
        • 7.3.5.2.2. By Method
        • 7.3.5.2.3. By Service Provider
        • 7.3.5.2.4. By Process Flow
        • 7.3.5.2.5. By Therapeutic Area
        • 7.3.5.2.6. By End-User

8. Asia Pacific Pharmacovigilance Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Clinical Trial Phase
    • 8.2.2. By Method
    • 8.2.3. By Service Provider
    • 8.2.4. By Process Flow
    • 8.2.5. By Therapeutic Area
    • 8.2.6. By End-User
    • 8.2.7. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pharmacovigilance Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Clinical Trial Phase
        • 8.3.1.2.2. By Method
        • 8.3.1.2.3. By Service Provider
        • 8.3.1.2.4. By Process Flow
        • 8.3.1.2.5. By Therapeutic Area
        • 8.3.1.2.6. By End-User
    • 8.3.2. India Pharmacovigilance Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Clinical Trial Phase
        • 8.3.2.2.2. By Method
        • 8.3.2.2.3. By Service Provider
        • 8.3.2.2.4. By Process Flow
        • 8.3.2.2.5. By Therapeutic Area
        • 8.3.2.2.6. By End-User
    • 8.3.3. Japan Pharmacovigilance Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Clinical Trial Phase
        • 8.3.3.2.2. By Method
        • 8.3.3.2.3. By Service Provider
        • 8.3.3.2.4. By Process Flow
        • 8.3.3.2.5. By Therapeutic Area
        • 8.3.3.2.6. By End-User
    • 8.3.4. South Korea Pharmacovigilance Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Clinical Trial Phase
        • 8.3.4.2.2. By Method
        • 8.3.4.2.3. By Service Provider
        • 8.3.4.2.4. By Process Flow
        • 8.3.4.2.5. By Therapeutic Area
        • 8.3.4.2.6. By End-User
    • 8.3.5. Australia Pharmacovigilance Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Clinical Trial Phase
        • 8.3.5.2.2. By Method
        • 8.3.5.2.3. By Service Provider
        • 8.3.5.2.4. By Process Flow
        • 8.3.5.2.5. By Therapeutic Area
        • 8.3.5.2.6. By End-User

9. Middle East & Africa Pharmacovigilance Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Clinical Trial Phase
    • 9.2.2. By Method
    • 9.2.3. By Service Provider
    • 9.2.4. By Process Flow
    • 9.2.5. By Therapeutic Area
    • 9.2.6. By End-User
    • 9.2.7. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pharmacovigilance Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Clinical Trial Phase
        • 9.3.1.2.2. By Method
        • 9.3.1.2.3. By Service Provider
        • 9.3.1.2.4. By Process Flow
        • 9.3.1.2.5. By Therapeutic Area
        • 9.3.1.2.6. By End-User
    • 9.3.2. UAE Pharmacovigilance Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Clinical Trial Phase
        • 9.3.2.2.2. By Method
        • 9.3.2.2.3. By Service Provider
        • 9.3.2.2.4. By Process Flow
        • 9.3.2.2.5. By Therapeutic Area
        • 9.3.2.2.6. By End-User
    • 9.3.3. South Africa Pharmacovigilance Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Clinical Trial Phase
        • 9.3.3.2.2. By Method
        • 9.3.3.2.3. By Service Provider
        • 9.3.3.2.4. By Process Flow
        • 9.3.3.2.5. By Therapeutic Area
        • 9.3.3.2.6. By End-User

10. South America Pharmacovigilance Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Clinical Trial Phase
    • 10.2.2. By Method
    • 10.2.3. By Service Provider
    • 10.2.4. By Process Flow
    • 10.2.5. By Therapeutic Area
    • 10.2.6. By End-User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharmacovigilance Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Clinical Trial Phase
        • 10.3.1.2.2. By Method
        • 10.3.1.2.3. By Service Provider
        • 10.3.1.2.4. By Process Flow
        • 10.3.1.2.5. By Therapeutic Area
        • 10.3.1.2.6. By End-User
    • 10.3.2. Colombia Pharmacovigilance Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Clinical Trial Phase
        • 10.3.2.2.2. By Method
        • 10.3.2.2.3. By Service Provider
        • 10.3.2.2.4. By Process Flow
        • 10.3.2.2.5. By Therapeutic Area
        • 10.3.2.2.6. By End-User
    • 10.3.3. Argentina Pharmacovigilance Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Clinical Trial Phase
        • 10.3.3.2.2. By Method
        • 10.3.3.2.3. By Service Provider
        • 10.3.3.2.4. By Process Flow
        • 10.3.3.2.5. By Therapeutic Area
        • 10.3.3.2.6. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pharmacovigilance Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. IQVIA Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. ArisGlobal
  • 15.3. Parexel International Corporation
  • 15.4. Labcorp Drug Development
  • 15.5. Accenture
  • 15.6. Cognizant Technology Solutions
  • 15.7. Ergomed Group
  • 15.8. ICON plc
  • 15.9. Syneos Health
  • 15.10. Wipro Limited

16. Strategic Recommendations

17. About Us & Disclaimer